Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

Core Insights - Kalaris Therapeutics, Inc. announced the presentation of clinical data from its Phase 1 study of TH103 at the 49th Annual Meeting of the Macula Society, scheduled for February 25-28, 2026, in San Diego, California [1][2] Company Overview - Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases [5] - The company was founded by Dr. Napoleone Ferrara, a pioneer in anti-VEGF therapy, and aims to advance novel therapeutic approaches for patients with sight-threatening retinal conditions [5] Product Details - TH103 is a novel investigational therapy designed to enhance VEGF inhibition and increase intraocular retention, developed by Dr. Napoleone Ferrara [2] - The upcoming presentation will cover safety, tolerability, pharmacokinetics, and early efficacy outcomes of TH103 in patients with treatment-naive neovascular age-related macular degeneration [2] Presentation Information - The presentation will be part of a scientific session attended by leading retinal specialists and clinical investigators [2][4] - The specific details of the presentation include the title "First-in-Human Evaluation of TH103, a Dual-Targeting VEGF and HSPG Inhibitor: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD," scheduled for February 26, 2026, at 8:15 am PT [6]